Literature DB >> 30114393

Prenatal intent and postpartum receipt of long-acting reversible contraception among women receiving medication-assisted treatment for opioid use disorder.

Anupama Kotha1, Beatrice A Chen2, Lauren Lewis3, Shannon Dunn4, Katherine P Himes2, Elizabeth E Krans5.   

Abstract

BACKGROUND: Many women with opioid use disorder (OUD) do not use highly effective postpartum contraception such as long-acting reversible contraception (LARC). We evaluated factors associated with prenatal intent and postpartum receipt of LARC among women receiving medication-assisted treatment (MAT) for OUD. STUDY
DESIGN: This was a retrospective cohort study of 791 pregnant women with OUD on MAT who delivered at an academic institution without immediate postpartum LARC services between 2009 and 2012. LARC intent was defined as a documented plan for postpartum LARC during pregnancy and LARC receipt was defined as documentation of LARC placement by 8 weeks postpartum. We organized contraceptive methods into five categories: LARC, female sterilization, short-acting methods, barrier methods and no documented method. Multivariable logistic regression identified characteristics predictive of prenatal LARC intent and postpartum LARC receipt.
RESULTS: Among 791 pregnant women with OUD on MAT, 275 (34.8%) intended to use postpartum LARC and only 237 (29.9%) attended the postpartum visit. Among 275 women with prenatal LARC intent, 124 (45.1%) attended their postpartum visit and 50 (18.2%) received a postpartum LARC. Prenatal contraceptive counseling (OR 6.67; 95% CI 3.21, 13.89) was positively associated with LARC intent. Conversely, older age (OR 0.95; 95% CI 0.91, 0.98) and private practice provider (OR 0.48; 95% CI 0.32, 0.72) were negatively associated with LARC intent. Although parity was not predictive of LARC intent, primiparous patients (CI 0.49; 95% CI 0.26, 0.97) were less likely to receive postpartum LARC.
CONCLUSIONS: Discrepancies exist between prenatal intent and postpartum receipt of LARC among pregnant women with OUD on MAT. Immediate postpartum LARC services may reduce LARC access barriers. IMPLICATIONS: Despite prenatal interest in using LARC, most pregnant women with OUD on MAT did not receive postpartum LARC. The provision of immediate postpartum LARC services may reduce barriers to postpartum LARC receipt such as poor attendance at the postpartum visit.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Long-acting reversible contraception; Opioid use disorder; Postpartum contraception; Pregnancy

Mesh:

Year:  2018        PMID: 30114393      PMCID: PMC6289834          DOI: 10.1016/j.contraception.2018.08.008

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  22 in total

1.  Knowledge of and concerns about long-acting reversible contraception among women in medication-assisted treatment for opioid use disorder.

Authors:  Alexis K Matusiewicz; Heidi S Melbostad; Sarah H Heil
Journal:  Contraception       Date:  2017-08-02       Impact factor: 3.375

2.  Unintended pregnancy in opioid-abusing women.

Authors:  Sarah H Heil; Hendree E Jones; Amelia Arria; Karol Kaltenbach; Mara Coyle; Gabriele Fischer; Susan Stine; Peter Selby; Peter R Martin
Journal:  J Subst Abuse Treat       Date:  2010-10-30

Review 3.  Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review.

Authors:  Mishka Terplan; Dennis J Hand; Melissa Hutchinson; Elizabeth Salisbury-Afshar; Sarah H Heil
Journal:  Prev Med       Date:  2015-04-18       Impact factor: 4.018

4.  Factors associated with buprenorphine versus methadone use in pregnancy.

Authors:  Elizabeth E Krans; Debra Bogen; Gale Richardson; Seo Young Park; Shannon L Dunn; Nancy Day
Journal:  Subst Abus       Date:  2016-02-25       Impact factor: 3.716

5.  Barriers to intrauterine device insertion in postpartum women.

Authors:  Joseph A Tony Ogburn; Eve Espey; Jody Stonehocker
Journal:  Contraception       Date:  2005-08-09       Impact factor: 3.375

6.  Implementing Immediate Postpartum Long-Acting Reversible Contraception Programs.

Authors:  Lisa G Hofler; Sarah Cordes; Carrie A Cwiak; Peggy Goedken; Denise J Jamieson; Melissa Kottke
Journal:  Obstet Gynecol       Date:  2017-01       Impact factor: 7.661

7.  Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices.

Authors: 
Journal:  Obstet Gynecol       Date:  2017-11       Impact factor: 7.661

8.  Declines in Unintended Pregnancy in the United States, 2008-2011.

Authors:  Lawrence B Finer; Mia R Zolna
Journal:  N Engl J Med       Date:  2016-03-03       Impact factor: 91.245

9.  Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations.

Authors:  Elizabeth E Krans; Gerald Cochran; Debra L Bogen
Journal:  Clin Obstet Gynecol       Date:  2015-06       Impact factor: 2.190

10.  Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: A retrospective cohort study.

Authors:  Elizabeth E Krans; Susan L Zickmund; Vinod K Rustgi; Seo Young Park; Shannon L Dunn; Eleanor B Schwarz
Journal:  Subst Abus       Date:  2015-11-16       Impact factor: 3.716

View more
  3 in total

1.  Contraceptive Method Choices in Women With and Without Opioid Use Who Have Infants in the Neonatal Intensive Care Unit and Nursery.

Authors:  Alia Radwan; Bobbie Nicole Ray; David M Haas
Journal:  Womens Health Rep (New Rochelle)       Date:  2020-09-24

2.  Increasing access to family planning services among women receiving medications for opioid use disorder: A pilot randomized trial examining a peer-led navigation intervention.

Authors:  Deborah J Rinehart; Melanie Stowell; Adriana Collings; M Joshua Durfee; Tara Thomas-Gale; Hendrée E Jones; Ingrid Binswanger
Journal:  J Subst Abuse Treat       Date:  2021-02-04

3.  Long-acting reversible contraceptives (LARCs) as harm reduction: a qualitative study exploring views of women with histories of opioid misuse.

Authors:  Stephani L Stancil; Melissa K Miller; Alex Duello; Sarah Finocchario-Kessler; Kathy Goggin; Rachel P Winograd; Emily A Hurley
Journal:  Harm Reduct J       Date:  2021-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.